BR112022010680A2 - Proteínas de ligação ao antígeno associado ao interferon e uso das mesmas - Google Patents
Proteínas de ligação ao antígeno associado ao interferon e uso das mesmasInfo
- Publication number
- BR112022010680A2 BR112022010680A2 BR112022010680A BR112022010680A BR112022010680A2 BR 112022010680 A2 BR112022010680 A2 BR 112022010680A2 BR 112022010680 A BR112022010680 A BR 112022010680A BR 112022010680 A BR112022010680 A BR 112022010680A BR 112022010680 A2 BR112022010680 A2 BR 112022010680A2
- Authority
- BR
- Brazil
- Prior art keywords
- interferon
- binding proteins
- associated antigen
- vectors
- nucleic acids
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title abstract 8
- 108010050904 Interferons Proteins 0.000 title abstract 8
- 102000025171 antigen binding proteins Human genes 0.000 title abstract 8
- 108091000831 antigen binding proteins Proteins 0.000 title abstract 8
- 229940079322 interferon Drugs 0.000 title abstract 8
- 239000013598 vector Substances 0.000 abstract 8
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 241000700721 Hepatitis B virus Species 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
PROTEÍNAS DE LIGAÇÃO AO ANTÍGENO ASSOCIADO AO INTERFERON E USO DAS MESMAS. A presente invenção refere-se às novas proteínas de ligação ao antígeno associado ao interferon, bem como aos ácidos nucleicos, vetores e sistemas de vetor que codificam tais proteínas de ligação ao antígeno associado ao interferon. A presente invenção também se refere às composições farmacêuticas que compreendem as proteínas de ligação ao antígeno associado ao interferon, ácidos nucleicos, vetores e sistemas de vetor. As novas proteínas de ligação ao antígeno associado ao interferon fornecem melhoras benéficas sobre o estado atual da técnica, por exemplo, pelo fato de que elas interrompem eficazmente a replicação viral e, assim, reduzem a carga viral do HBV. Assim, a presente invenção também fornece usos médicos de tais proteínas de ligação ao antígeno associado ao interferon, ácidos nucleicos, vetores, sistemas de vetor e composições, por exemplo, no tratamento da infecção pelo vírus da hepatite B (HBV) e/ou para reduzir um ou mais sintomas de infecção por HBV em um indivíduo. A presente invenção também fornece células hospedeiras que compreendem tais ácidos nucleicos, vetores e sistemas de vetores, bem como métodos de produção das proteínas de ligação ao antígeno associado ao interferon de acordo com a invenção usando as referidas células hospedeiras.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19306552 | 2019-12-03 | ||
| EP19306573 | 2019-12-04 | ||
| PCT/EP2020/083745 WO2021110562A1 (en) | 2019-12-03 | 2020-11-27 | Interferon-associated antigen binding proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010680A2 true BR112022010680A2 (pt) | 2022-08-16 |
Family
ID=73554458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010680A BR112022010680A2 (pt) | 2019-12-03 | 2020-11-27 | Proteínas de ligação ao antígeno associado ao interferon e uso das mesmas |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230242655A1 (pt) |
| EP (1) | EP4069291A1 (pt) |
| JP (1) | JP2023505168A (pt) |
| KR (1) | KR20220109436A (pt) |
| CN (1) | CN115052625B (pt) |
| AU (1) | AU2020398327A1 (pt) |
| BR (1) | BR112022010680A2 (pt) |
| CA (1) | CA3163358A1 (pt) |
| IL (1) | IL293450A (pt) |
| WO (1) | WO2021110562A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024521958A (ja) * | 2021-06-09 | 2024-06-04 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | コロナウイルス感染の処置又は予防のための使用のためのインターフェロン会合抗原結合性タンパク質 |
| WO2024213635A1 (en) * | 2023-04-12 | 2024-10-17 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| DE3681787D1 (de) | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| EP0633318A1 (en) | 1987-09-11 | 1995-01-11 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
| EP0391960B1 (en) | 1987-12-11 | 1994-08-17 | Whitehead Institute For Biomedical Research | Genetic modification of endothelial cells |
| EP0732397A3 (en) | 1988-02-05 | 1996-10-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JP3249516B2 (ja) | 1990-10-31 | 2002-01-21 | ソマティクス セラピー コーポレイション | 遺伝子治療のためのレトロウイルスのベクター |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| AU693436B2 (en) | 1993-03-09 | 1998-07-02 | Genzyme Corporation | Isolation of components of interest from milk |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| CN104357469B (zh) * | 2006-05-03 | 2018-10-26 | 科罗拉多州立大学董事会 | Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其用途 |
| AU2010286642B2 (en) * | 2009-08-31 | 2016-03-10 | Ibc Pharmaceuticals, Inc. | Bispecific immunocytokine dock-and-lock (DNL) complexes and therapeutic use thereof |
| KR20130049196A (ko) * | 2010-08-05 | 2013-05-13 | 에프. 호프만-라 로슈 아게 | 항-mhc 항체 항-바이러스성 사이토카인 융합 단백질 |
| CA2809433A1 (en) * | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2014028502A1 (en) * | 2012-08-13 | 2014-02-20 | ImmunGene Inc. | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
| WO2014028560A2 (en) * | 2012-08-14 | 2014-02-20 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| BR112017025693A2 (pt) * | 2015-05-29 | 2018-08-14 | Abbvie Inc. | anticorpos anti-cd40 e seus usos |
| SG11201807677YA (en) * | 2016-03-04 | 2018-10-30 | Univ Rockefeller | Antibodies to cd40 with enhanced agonist activity |
| RS62726B1 (sr) * | 2016-05-27 | 2022-01-31 | Abbvie Biotherapeutics Inc | Anti-cd40 antitela i njihove upotrebe |
| WO2018087345A1 (en) * | 2016-11-14 | 2018-05-17 | F. Hoffmann-La Roche Ag | COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON |
| CN112912098A (zh) * | 2018-06-01 | 2021-06-04 | 赛诺菲 | 用于治疗乙型肝炎病毒感染的组合疗法 |
-
2020
- 2020-11-27 US US17/756,803 patent/US20230242655A1/en active Pending
- 2020-11-27 WO PCT/EP2020/083745 patent/WO2021110562A1/en active Application Filing
- 2020-11-27 JP JP2022533106A patent/JP2023505168A/ja active Pending
- 2020-11-27 CA CA3163358A patent/CA3163358A1/en active Pending
- 2020-11-27 CN CN202080095487.XA patent/CN115052625B/zh active Active
- 2020-11-27 AU AU2020398327A patent/AU2020398327A1/en active Pending
- 2020-11-27 KR KR1020227022262A patent/KR20220109436A/ko unknown
- 2020-11-27 IL IL293450A patent/IL293450A/en unknown
- 2020-11-27 EP EP20812049.3A patent/EP4069291A1/en active Pending
- 2020-11-27 BR BR112022010680A patent/BR112022010680A2/pt unknown
-
2023
- 2023-01-11 US US18/152,969 patent/US20230279137A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220109436A (ko) | 2022-08-04 |
| CN115052625B (zh) | 2024-11-01 |
| AU2020398327A1 (en) | 2022-07-14 |
| IL293450A (en) | 2022-07-01 |
| US20230242655A1 (en) | 2023-08-03 |
| CN115052625A (zh) | 2022-09-13 |
| CA3163358A1 (en) | 2021-06-10 |
| WO2021110562A1 (en) | 2021-06-10 |
| EP4069291A1 (en) | 2022-10-12 |
| JP2023505168A (ja) | 2023-02-08 |
| US20230279137A1 (en) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010425A2 (pt) | Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b | |
| BR112022010680A2 (pt) | Proteínas de ligação ao antígeno associado ao interferon e uso das mesmas | |
| BR112019007433A2 (pt) | sistemas de replicon de vírus recombinante e usos dos mesmos | |
| BR112022015628A2 (pt) | Vacina de sars-cov-2 | |
| BR112016007868A2 (pt) | vacinas contra o vírus de epstein-barr | |
| Irie et al. | Inhibition of interferon regulatory factor 3 activation by paramyxovirus V protein | |
| BR112022001185A2 (pt) | Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos | |
| BR112018011122A2 (pt) | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos | |
| BR112017020986A2 (pt) | proteínas de ligação recombinantes e seu uso | |
| BR112018068391A2 (pt) | sistema e métodos para produzir uma proteína, célula inoculada, construção de rna para expressar a replicase de alfavírus e dna | |
| BR112021024786A2 (pt) | Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada | |
| BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
| BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
| EP3308798A3 (en) | Polypeptides and antibodies for treating hbv infection and related diseases | |
| BR112013032251A2 (pt) | composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina | |
| Ariumi | Host cellular RNA helicases regulate SARS-CoV-2 infection | |
| BR112022027038A2 (pt) | Vacinas de replicon de rna contra hbv | |
| BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
| BRPI0821034A8 (pt) | Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação | |
| BR112022011099A2 (pt) | Tratamento de doenças relacionadas ao vírus da hepatite b | |
| PE20090653A1 (es) | Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc | |
| BR112018068342A2 (pt) | vacina de vírus zika vivo atenuado | |
| BR112022000724A2 (pt) | Proteínas de capsídeo de aav modificado para tratamento de doença artrítica | |
| Sun et al. | Comparative virus replication and host innate responses in human cells infected with three prevalent clades (2.3. 4, 2.3. 2, and 7) of highly pathogenic avian influenza H5N1 viruses | |
| BR112018003580A2 (pt) | molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante |